Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Vastra Gotaland Region
H. Lee Moffitt Cancer Center and Research Institute
The Netherlands Cancer Institute
Centre Hospitalier Universitaire Vaudois
University Hospital, Basel, Switzerland
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Beth Israel Deaconess Medical Center
Fate Therapeutics
University Health Network, Toronto
Herlev Hospital
M.D. Anderson Cancer Center
Herlev Hospital
M.D. Anderson Cancer Center
Mayo Clinic
Milton S. Hershey Medical Center
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Nantes University Hospital
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Oslo University Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Herlev Hospital
University Hospital Tuebingen
University of Utah
Northwestern University
SWOG Cancer Research Network
University of Virginia
Fred Hutchinson Cancer Center
University of Chicago
California Pacific Medical Center Research Institute
National Institutes of Health Clinical Center (CC)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)